BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mikelez-Alonso I, Magadán S, González-Fernández Á, Borrego F. Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity. Adv Drug Deliv Rev 2021;176:113860. [PMID: 34237404 DOI: 10.1016/j.addr.2021.113860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu H, Jacquelot N, Belz GT. Metabolic features of innate lymphoid cells. J Exp Med 2022;219:e20221140. [PMID: 36301303 DOI: 10.1084/jem.20221140] [Reference Citation Analysis]
2 Murugan D, Murugesan V, Panchapakesan B, Rangasamy L. Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. Cancers 2022;14:5438. [DOI: 10.3390/cancers14215438] [Reference Citation Analysis]
3 Dobrovolskaia MA. Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory. Front Immunol 2022;13:984252. [DOI: 10.3389/fimmu.2022.984252] [Reference Citation Analysis]
4 Uthaman S, Cutshaw G, Ghazvini S, Bardhan R. Nanomaterials for Natural Killer Cell-Based Immunoimaging and Immunotherapies in Cancer. ACS Appl Mater Interfaces 2022. [PMID: 36006784 DOI: 10.1021/acsami.2c08619] [Reference Citation Analysis]
5 Tian Z, Yao W. PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas. Front Immunol 2022;13:898255. [DOI: 10.3389/fimmu.2022.898255] [Reference Citation Analysis]
6 Zhao Y, Liu T, Zhou M. Immune-Cell-Derived Exosomes for Cancer Therapy. Mol Pharm 2022. [PMID: 35876318 DOI: 10.1021/acs.molpharmaceut.2c00407] [Reference Citation Analysis]
7 Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M. Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World J Clin Oncol 2022; 13(7): 553-566 [DOI: 10.5306/wjco.v13.i7.553] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khalifa AM, Nakamura T, Sato Y, Sato T, Hyodo M, Hayakawa Y, Harashima H. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. Int J Pharm 2022;624:122034. [PMID: 35863595 DOI: 10.1016/j.ijpharm.2022.122034] [Reference Citation Analysis]
9 Raza A, Rossi GR, Janjua TI, Souza-Fonseca-Guimaraes F, Popat A. Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy. Trends Biotechnol 2022:S0167-7799(22)00151-2. [PMID: 35840426 DOI: 10.1016/j.tibtech.2022.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Peng G, Fadeel B. Understanding the bidirectional interactions between two-dimensional materials, microorganisms, and the immune system. Adv Drug Deliv Rev 2022;188:114422. [PMID: 35810883 DOI: 10.1016/j.addr.2022.114422] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Liu J, Liu Z, Pang Y, Zhou H. The interaction between nanoparticles and immune system: application in the treatment of inflammatory diseases. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01343-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Dobrovolskaia MA, Afonin KA, González-Fernández Á. Editorial to "Journey into the immunological properties of engineered nanomaterials: There and back again". Adv Drug Deliv Rev 2022;181:114100. [PMID: 34954314 DOI: 10.1016/j.addr.2021.114100] [Reference Citation Analysis]
13 Michel T, Ollert M, Zimmer J. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. Int J Mol Sci 2022;23:797. [PMID: 35054985 DOI: 10.3390/ijms23020797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]